Open AccessCATESTATIN AS A NOVEL MARKER OF CARDIOVASCULAR RISK IN SYSTEMIC HYPERTENSION
Author(s) -
E. Yu. Gubareva,
Н. Н. Крюков,
И. В. Губарева
Publication year - 2018
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2018-4-111-116
Subject(s) - medicine , chromogranin a , risk stratification , essential hypertension , protease , endocrinology , cardiology , bioinformatics , pharmacology , blood pressure , enzyme , biochemistry , biology , immunohistochemistry
Review of the key studies on antihypertensive, vasodilatatory, angiogenic and antiapoptotic action of catestatin — a peptide resulting from endogenic protease interaction with chromogranin А. Plasma levels of catestatin correlate negatively with the hypertension phenotype. Pathogenetic role is discussed for catestatin in development of essential hypertension and its possible influence as a marker of cardiovascular risk stratification.